Last quarter (Q4 2023), Aldeyra Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Aldeyra Therapeutics's net income was $-4.75M. See Aldeyra Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 42.79M	$ 42.79M	$ 62.68M	$ 56.22M	$ 34.67M	$ 56.51M
Operating Income	$ -42.79M	$ -42.79M	$ -62.68M	$ -56.22M	$ -34.67M	$ -56.51M
Net Non Operating Interest Income Expense	$ 5.25M	$ 5.25M	$ 655.35K	$ -1.56M	$ -1.61M	$ 937.50K
Other Income Expense	$ -100.00K	$ -100.00K	-	-	$ -1.75M	$ -6.57M
Pretax Income	$ -37.54M	$ -37.54M	$ -62.02M	$ -57.78M	$ -38.03M	$ -62.14M
Tax Provision	-	-	-	-	$ -479.26K	$ -1.31M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -37.54M	$ -37.50M	$ -62.02M	$ -57.78M	$ -37.55M	$ -60.83M
Basic EPS	$ -0.64	$ -0.64	$ -1.06	$ -1.07	$ -1.11	$ -2.24
Diluted EPS	$ -0.10	$ -0.64	$ -1.06	$ -1.07	$ -1.11	$ -2.24
Basic Average Shares	$ 234.38M	$ 58.59M	$ 58.41M	$ 54.04M	$ 33.97M	$ 27.11M
Diluted Average Shares	$ 234.38M	$ 58.59M	$ 58.41M	$ 54.04M	$ 33.97M	$ 27.11M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 42.79M	$ 42.79M	$ 62.68M	$ 56.22M	$ 34.67M	$ 56.51M
Net Income From Continuing And Discontinued Operation	$ -37.50M	$ -37.50M	$ -62.00M	$ -57.78M	$ -37.55M	$ -60.83M
Normalized Income	$ -17.32M	$ -29.66M	-	-	$ -35.82M	$ -54.40M
Interest Expense	-	-	-	-	$ 1.90M	$ 603.85K
EBIT	$ -35.47M	$ -35.47M	$ -60.33M	$ -56.03M	$ -36.13M	$ -61.53M
EBITDA	$ -34.87M	$ -34.87M	$ -59.79M	$ -55.36M	$ -36.07M	$ -61.44M

Currency in USD

Aldeyra Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing